Company Profile
Erasca Stock Price, News & Analysis
- Ticker:
- ERAS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
18.27 USD (-1.88%)
Close
Last updated: August 6, 2026
4.19B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, ERAS closed down 1.88% at $18.27. No new same-company headline was identified in the current news window.
Company overview
RAS/MAPK Precision Oncology
Erasca is a clinical-stage precision-oncology company developing therapies for cancers driven by the RAS/MAPK pathway. Its portfolio is designed to address genetically defined tumors through direct and pathway-level inhibition.
ERAS-0015
ERAS-0015 is a RAS-targeted clinical candidate being evaluated in tumors including KRAS-mutated non-small cell lung and pancreatic cancers. Development includes monotherapy expansion and combination work with pembrolizumab.
ERAS-4001
ERAS-4001 is a pan-KRAS inhibitor in Phase 1 dose escalation. The program is intended to broaden coverage across KRAS-driven tumors beyond individual mutation subtypes.
Future catalysts
Preliminary Phase 1 monotherapy data for ERAS-4001 in the second half of 2026.
ERAS-0015 monotherapy-expansion and combination dose-escalation data in the first half of 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Erasca (ERAS)?
Erasca (ERAS) most recently closed at 18.27 USD, a -1.88% move versus the previous session.
What is the market cap of Erasca (ERAS)?
Erasca currently has a market capitalization of 4.19B USD on BioPharmSignal.
What does Erasca do?
RAS/MAPK Precision Oncology Erasca is a clinical-stage precision-oncology company developing therapies for cancers driven by the RAS/MAPK pathway. Its portfolio is designed to address genetically defined tumors through direct and pathway-level inhibition. ERAS-0015 ERAS-0015 is a RAS-targeted clinical candidate being evaluated in tumors including...
On which exchange is ERAS stock listed?
Erasca (ERAS) is associated with NASDAQ, United States, Biopharma.
What is ERAS-0015?
ERAS-0015 monotherapy-expansion and combination dose-escalation data in the first half of 2027.
Which conditions is Erasca targeting with ERAS-0015?
Erasca is associated with oncology, cancer therapeutics, genetic disease based on its company overview and current catalyst commentary.
How does Erasca describe recent progress with ERAS-0015?
ERAS-0015 monotherapy-expansion and combination dose-escalation data in the first half of 2027.
What is ERAS-4001?
ERAS-4001 ERAS-4001 is a pan-KRAS inhibitor in Phase 1 dose escalation.